On August 11, 2025, Roivant Sciences reported its financial results for the first quarter ended June 30, 2025. The company announced consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately $4.5 billion as of June 30, 2025. This cash position provides a runway for its operations and pipeline.
For the first quarter, revenue was slightly under $2.2 million, a decrease from nearly $8 million in the same quarter of the prior year. The company reported a GAAP net loss of $273.9 million, or $0.33 per share, compared to a net profit of $95 million, or $0.01 per share, in the year-ago quarter. Research and development (R&D) expenses increased by $32.4 million to $152.9 million, driven by increased program-specific costs for the anti-FcRn franchise, mosliciguat, and brepocitinib.
Despite the net loss, Roivant announced the completion of its initial $1.5 billion share repurchase program. Concurrently, the company's board of directors authorized an additional $500 million share repurchase program. This new authorization reflects Roivant's ongoing commitment to returning capital to shareholders and increasing exposure to its existing and future programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.